Executive Summary
Tygan University Hospitals is a national hospital-city programme with the hospital as the anchor tenant, not the whole project.
The programme combines healthcare, medical education, biotechnology, medical tourism, community care, energy, water, data, food production, logistics, hospitality, and local enterprise development into one provincial ecosystem model. Each campus is intended to serve both local communities and private/international patients while supporting training, research, and long-term regional development.
Core model
- One flagship hospital ecosystem per South African province.
- 100 executive/private beds for premium procedures, private recovery, visiting medical professionals, and medical tourism.
- 500 general beds for university-linked tertiary hospital care, specialist services, emergency pathways, surgery, ICU, maternity, pediatrics, rehabilitation, and general care.
- Community/social beds and community care centres for free or subsidised access, chronic care, screening, follow-up, maternal care, prevention, and mobile clinic integration.
- Tourism and nature-reserve proximity to support recovery, family accommodation, wellness, hospitality, and private-sector income.
9-Province Rollout
The nine-province plan creates a national network, with each flagship adapted to its province rather than copied blindly.
Each site must be screened for land availability, airports, roads, universities, workforce, emergency access, water, power, fibre, environmental sensitivity, community health demand, tourism strength, and government readiness. Preferred locations should sit near major nature reserves, coastal tourism corridors, mountain ranges, heritage routes, or established tourism economies.
Rollout logic
- Phase 1: Gauteng flagship and national operating standard.
- Phase 2: provinces with the best combination of health demand, tourism pull, government readiness, and infrastructure access.
- Phase 3: replication into remaining provinces with lessons from the first sites.
- Phase 4: national biotech, procurement, training, data, research, food, and infrastructure platforms scaling across all campuses.
Site-selection scorecard
- Transport: airport, road, ambulance, emergency, and logistics access.
- Utilities: water security, renewable energy capacity, waste management, fibre, and data-centre resilience.
- Tourism: reserve/coast/mountain/heritage proximity and private recovery value.
- Community: local disease burden, poverty impact, workforce readiness, and training benefit.
Campus Model
The campus should feel like one integrated ecosystem while keeping sensitive patient flows properly separated.
The executive/private side, university/general side, and community wing must each have their own experience, access control, and operational rhythm. Shared clinical services can still connect the whole system through diagnostics, theatres, pharmacy, labs, imaging, emergency command, medical gas, sterile services, infection control, data, logistics, and utilities.
Campus zones
- Executive wing: 100 premium beds, private recovery suites, visiting specialist access, family accommodation, concierge care, and holiday-linked recovery.
- University hospital: 500 beds, specialist departments, training, research, teaching theatres, ICU, trauma, maternity, pediatrics, oncology, neurology, orthopedics, rehabilitation, and general wards.
- Community wing: social/free beds, screening, chronic-care follow-up, maternal health, mobile clinic referrals, prevention, vaccinations, and local outreach.
- Shared backbone: robotic pharmacy, diagnostics, laboratories, imaging, theatres, blood bank, sterile services, data, security, logistics, and emergency command.
Gene Therapy Platform
Gene therapy is no longer a placeholder: it is treated as a Tygan-owned or Tygan-controlled patent platform from launch.
The project assumption is that Tygan enters the programme with the required gene therapy patents already secured, owned, assigned, or exclusively controlled. The business plan must still keep a clear line between patent ownership and clinical approval. Treatment pathways must be built through proper research, ethics, regulatory, consent, and patient-safety controls.
Governance requirements
- Patent/IP register, chain-of-title evidence, assignment/licence records, territory rights, and freedom-to-operate review.
- SAHPRA pathway, ethics approval, clinical protocols, informed consent, adverse-event reporting, and specialist oversight.
- Genomic data protection, patient registry, long-term monitoring, and clear separation between approved therapy, research, and future pipeline work.
- Private and community access models designed ethically, without selling unapproved medical claims.
Regenerative Medicine
Regenerative medicine should be a national Tygan biotech platform with provincial clinical nodes.
The Stemedica/Stemdedia source pack is treated as a strategic due-diligence input for cell therapy, cGMP manufacturing, cell banking, clinical trial networks, training, pharmacovigilance, advanced rehabilitation, and medical-tourism pathways where approved.
Platform components
- National regenerative medicine and cell therapy centre of excellence.
- South African cGMP biomanufacturing and cell-banking hub with backup/disaster recovery capability.
- Provincial regenerative medicine nodes in each hospital ecosystem.
- Clinical trial network across all nine provinces.
- Training institute for doctors, nurses, lab teams, QA/QC, GMP staff, trial coordinators, and pharmacovigilance teams.
AI, Nano, Natural, Robotics
The hospital should be designed as a hyper-intelligent care environment where technology supports clinicians and governance.
The stack includes AI triage, AI-assisted radiology/pathology review, predictive bed management, infection surveillance, remote monitoring, scheduling, patient-risk scoring, digital twin campus operations, robotic pharmacy, nanomedicine research, and clinically governed natural/herbal workstreams.
Medicine management
- Robotic dispensing, automated medicine storage, controlled-drug vault automation, unit-dose packaging, and recall management.
- Barcode/RFID medicine tracking from prescription to pharmacy to bedside administration.
- Cold-chain medicine monitoring, expiry control, stock forecasting, and full medication audit trail.
Advanced care research
- Nanomedicine: targeted delivery, biosensors, antimicrobial materials, wound-healing applications, and lab-on-chip diagnostics.
- Natural and herbal medicine: plant-based therapeutics, nutrition, traditional remedy research, and recovery nutrition under clinical governance.
Infrastructure Spine
The ecosystem needs its own infrastructure spine so the hospital is not fragile in a power, water, data, or logistics shock.
Each campus should be supported by resilient power, water purification, wastewater recovery, waste-to-energy, biofuels, medical waste controls, gas and utility pipelines, logistics, retail, staff/community housing, organic farms, and redundant South African data-centre architecture.
Hard infrastructure
- Own power, microgrid, renewable generation, storage, and emergency backup.
- Water purification, wastewater treatment, emergency water storage, and reuse pathways.
- Green waste management, biofuels, medical waste controls, and compliant disposal systems.
- Organic farms close to the hospital with related farms sustaining nutrition and food supply.
- At least two geographically separated South African data centres, plus campus edge nodes, encrypted replication, immutable backups, offline emergency access, and POPIA-grade data residency controls.
Investment & Costing
The hospital should be financed as a set of investable packages rather than a single vague megaproject.
The concept assumption is EUR 5B+ per province and EUR 45B+ for the nine-province programme before national platform costs, contingency, escalation, finance costs, and expansion. The financial model should separate clinical hospital capex from medical tourism, community care, biotech, data, power, water, farms, retail, housing, and logistics.
Major cost blocks
- Core hospital, theatres, ICU, diagnostics, wards, labs, pharmacy, sterile services, emergency, and medical gas.
- Executive wing, hotel/recovery accommodation, wellness, retail/mall, and tourism-linked patient services.
- Community wing, community care centres, mobile care, screening, and social access mechanisms.
- Gene therapy, regenerative medicine, cGMP/cell bank, research/trials, and training institute.
- Power, water, waste, biofuels, farms, pipelines, data centres, cybersecurity, logistics, roads, and housing.
- Professional fees, permits, environmental work, contingency, escalation, working capital, and finance costs.
Revenue engines
- Private medical tourism, executive beds, visiting specialist procedures, diagnostics, pharmacy, research, trials, education, hospitality, retail, food, energy, water, logistics, and public/private partnerships.
Due Diligence & Next Work
Before final investor use, the project needs a proper due-diligence and evidence room.
The website can present the concept, but the final investor pack must include support documents, rights schedules, partner confirmations, regulatory strategy, province scorecards, site options, clinical governance, legal structure, financial model, diagrams, and risk register.
Priority diligence
- Gene therapy patent chain-of-title, licensing, assignments, rights territories, and freedom-to-operate review.
- Stemedica/Stemdedia current status, IP, licences, clinical claims, safety data, commercial terms, and rights for South Africa/Africa.
- SAHPRA, ethics, hospital licensing, POPIA, data, environmental, land, municipal, and infrastructure approvals.
- Hospital operator partners, university partners, medical specialists, biotech partners, energy/water partners, tourism partners, and government counterparts.
- Detailed capex/opex, revenue ramp, funding stack, ROI sensitivity, phasing, procurement plan, and risk register.